|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2008-12-17
|
|
pubmed:abstractText |
In patients with autoimmune hepatitis, efficient immunosuppressive therapy is essential to avoid progression to cirrhosis. There is no established second line therapy for patients failing standard therapy with steroids and azathioprine. The aim of this study was to examine the possible role of mycophenolate mofetil (MMF) as second line treatment of autoimmune hepatitis (AIH).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1572-0241
|
|
pubmed:author |
pubmed-author:AdamsDavid HDH,
pubmed-author:BoecherWulfW,
pubmed-author:BuggischPeterP,
pubmed-author:DenzerUlrikeU,
pubmed-author:GallePeter RPR,
pubmed-author:HennesElke MEM,
pubmed-author:KanzlerStephanS,
pubmed-author:LohseAnsgar WAW,
pubmed-author:OoYe HYH,
pubmed-author:SchrammChristophC,
pubmed-author:SchuchmannMarcusM,
pubmed-author:WiegardChristianeC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3063-70
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Mycophenolate mofetil as second line therapy in autoimmune hepatitis?
|
|
pubmed:affiliation |
First Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
|
|
pubmed:publicationType |
Journal Article
|
